

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Dare Bioscience, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value

(Title of Class of Securities)

(CUSIP Number)

08/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☒ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	Lind Global Fund III LP
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a) ☒ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	DELAWARE
Number of Shares Beneficially	Sole Voting Power 51,094,890.00

Owned by Each Reporting Person With:	6	Shared Voting Power
		0.00
		Sole Dispositive Power
	7	1,094,890.00
		Shared Dispositive Power
	8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
		1,094,890.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
		☐
11	Percent of class represented by amount in row (9)	
		5.65 %
12	Type of Reporting Person (See Instructions)	
		PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 warrants to purchase shares of common stock (the "Series A Warrants"), and (iii) 1,094,890 warrants to purchase shares of common stock (the "Series B Warrants," together with the Series A Warrants, the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons	
1	Lind Global Partners III LLC
Check the appropriate box if a member of a Group (see instructions)	
2	☐ (a)
	☒ (b)
3	Sec Use Only
Citizenship or Place of Organization	
4	DELAWARE
Sole Voting Power	
5	1,094,890.00
Shared Voting Power	
6	0.00
Sole Dispositive Power	
7	1,094,890.00
Shared Dispositive Power	
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person

	1,094,890.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	5.65 %
12	Type of Reporting Person (See Instructions)
	OO

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	EASTON JEFF
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	UNITED STATES
	Sole Voting Power
5	1,094,890.00
Number of	Shared Voting Power
Shares	6
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	7
Reporting	1,094,890.00
Person	Shared Dispositive
With:	8
	Power
	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,094,890.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	5.65 %
12	Type of Reporting Person (See Instructions)
	IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the

Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Dare Bioscience, Inc.

Address of issuer's principal executive offices:

(b)

3655 Nobel Drive, Suite 260, San Diego, California, 92122

Item 2.

Name of person filing:

This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): Lind Global Fund III LP, a Delaware limited partnership; Lind Global Partners III LLC, a Delaware limited liability company; and Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.

(a)

Address or principal business office or, if none, residence:

(b)

The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022

Citizenship:

(c)

See Row 4 of cover page for each Reporting Person.

Title of class of securities:

(d)

Common Stock, \$0.0001 par value

(e)

CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k)

☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a)

See Row 9 of cover page for each Reporting Person.

Percent of class:

(b)

See Row 11 of cover page for each Reporting Person. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

(ii) Shared power to vote or to direct the vote:

See Row 6 of cover page for each Reporting Person.

(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each Reporting Person.

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable

Item 8. Identification and Classification of Members of the Group.
Not Applicable

Item 9. Notice of Dissolution of Group.
Not Applicable

Item 10. Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature: Lind Global Partners III LLC, its General Partner
Name/Title: Jeff Easton, Managing Member
Date: 08/28/2026

Lind Global Partners III LLC

Signature: Lind Global Partners III LLC
Name/Title: Jeff Easton, Managing Member
Date: 08/28/2026

EASTON JEFF

Signature: Jeff Easton
Name/Title: Jeff Easton, Managing Member
Date: 08/28/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

JOINT FILING AGREEMENT

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, \$0.0001 par value, of Daré Bioscience, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

August 28, 2026

LIND GLOBAL FUND III LP

By: Lind Global Partners III LLC
its General Partner

By: /s/ Jeff Easton
Name: Jeff Easton
Title: Managing Member

LIND GLOBAL PARTNERS III LLC

By: /s/ Jeff Easton
Name: Jeff Easton
Title: Managing Member

JEFF EASTON

By: /s/ Jeff Easton